Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

Related Articles by Review for PubMed (Select 22658127)

1.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M.

N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.

2.

Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.

Tang PA, Heng DY.

Curr Oncol Rep. 2013 Apr;15(2):98-104. doi: 10.1007/s11912-012-0284-2. Review.

PMID:
23263823
3.

PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.

Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G.

Cancer Treat Rev. 2015 Feb;41(2):114-21. doi: 10.1016/j.ctrv.2014.12.013. Epub 2015 Jan 6. Review.

PMID:
25586601
4.

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Ott PA, Hodi FS, Robert C.

Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143. Review.

5.

Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.

Merelli B, Massi D, Cattaneo L, MandalĂ  M.

Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002. Epub 2013 Aug 28. Review.

PMID:
24029602
6.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-782. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

PMID:
25823918
7.

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.

Hamid O, Carvajal RD.

Expert Opin Biol Ther. 2013 Jun;13(6):847-61. doi: 10.1517/14712598.2013.770836. Epub 2013 Feb 19. Review.

PMID:
23421934
8.

Immune modulation in cancer with antibodies.

Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD.

Annu Rev Med. 2014;65:185-202. doi: 10.1146/annurev-med-092012-112807. Epub 2013 Oct 30. Review.

PMID:
24188664
9.

Prospects for targeting PD-1 and PD-L1 in various tumor types.

Kim JW, Eder JP.

Oncology (Williston Park). 2014 Nov;28 Suppl 3:15-28. Review.

10.

Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.

Harshman LC, Choueiri TK, Drake C, Stephen Hodi F Jr.

Cancer J. 2014 Jul-Aug;20(4):272-80. doi: 10.1097/PPO.0000000000000055. Review.

PMID:
25098288
11.

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Reiss KA, Forde PM, Brahmer JR.

Immunotherapy. 2014;6(4):459-75. doi: 10.2217/imt.14.9. Review.

PMID:
24815784
12.

PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.

Dolan DE, Gupta S.

Cancer Control. 2014 Jul;21(3):231-7. Review.

13.

PD-1 as a potential target in cancer therapy.

McDermott DF, Atkins MB.

Cancer Med. 2013 Oct;2(5):662-73. doi: 10.1002/cam4.106. Epub 2013 Jul 21. Review.

14.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
15.

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.

Gettinger S, Herbst RS.

Cancer J. 2014 Jul-Aug;20(4):281-9. doi: 10.1097/PPO.0000000000000063. Review.

PMID:
25098289
16.

Prognostic and predictive markers for the new immunotherapies.

Mahoney KM, Atkins MB.

Oncology (Williston Park). 2014 Nov;28 Suppl 3:39-48. Review.

17.

Targeting the PD-1 pathway: a promising future for the treatment of melanoma.

Mamalis A, Garcha M, Jagdeo J.

Arch Dermatol Res. 2014 Aug;306(6):511-9. doi: 10.1007/s00403-014-1457-7. Epub 2014 Mar 11. Review.

PMID:
24615548
18.

Potential of new therapies like anti-PD1 in kidney cancer.

Gunturi A, McDermott DF.

Curr Treat Options Oncol. 2014 Mar;15(1):137-46. doi: 10.1007/s11864-013-0268-y. Review.

PMID:
24504486
19.

Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.

Von Pawel J.

Bull Cancer. 2004 May 1;91(5):E70-6. Review.

PMID:
15582898
20.

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Zielinski C, Knapp S, Mascaux C, Hirsch F.

Ann Oncol. 2013 May;24(5):1170-9. doi: 10.1093/annonc/mds647. Epub 2013 Feb 7. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk